• Something wrong with this record ?

Multiple pathways for natural product treatment of Parkinson's disease: A mini review

J. Li, X. Long, J. Hu, J. Bi, T. Zhou, X. Guo, C. Han, J. Huang, T. Wang, N. Xiong, Z. Lin,

. 2019 ; 60 (-) : 152954. [pub] 20190511

Language English Country Germany

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc19044799

Grant support
R01 DA021409 NIDA NIH HHS - United States

BACKGROUND: It is established that natural medicines for Parkinson's disease (PD) provide an antioxidant activity in preventing dopaminergic neurons from degeneration. However, the underlying and related molecular details remain poorly understood. METHODS AND AIM: We review published in vitro and rodent studies of natural products in PD models with the aim to identify common molecular pathways contributing to the treatment efficacy. Commonly regulated genes were identified through the systemic literature search and further analyzed from a network perspective. FINDINGS: Approximately thirty different types of natural products have been investigated for their ability to regulate protein density and gene activity in various experimental systems. Most were found to attenuate neurotoxin-induced regulations. Three common PD pathways are involved. The most studied pathway was neuronal development/anti-apoptosis consisting of Bax/Bcl-2, caspases 3/9, and MAPK signaling. Another well studied was anti-inflammation comprising iNOS, nNOS, Nrf2/ARE, cytokines, TNFα, COX2 and MAPK signaling. The third pathway referred to dopamine transmission modulation with upregulated VMAT2, DAT, NURR1 and GDNF levels. To date, HIPK2, a conserved serine/threonine kinase and transcriptional target of Nrf2 in an anti-apoptosis signaling pathway, is the first protein identified as the direct binding target of a natural product (ZMHC). IMPLICATIONS: Natural products may utilize multiple and intercellular pathways at various steps to prevent DA neurons from degeneration. Molecular delineation of the mechanisms of actions is revealing new, perhaps combinational therapeutic approaches to stop the progression of DA degeneration.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044799
003      
CZ-PrNML
005      
20200116105352.0
007      
ta
008      
200109s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.phymed.2019.152954 $2 doi
035    __
$a (PubMed)31130327
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Li, Jingwen $u Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
245    10
$a Multiple pathways for natural product treatment of Parkinson's disease: A mini review / $c J. Li, X. Long, J. Hu, J. Bi, T. Zhou, X. Guo, C. Han, J. Huang, T. Wang, N. Xiong, Z. Lin,
520    9_
$a BACKGROUND: It is established that natural medicines for Parkinson's disease (PD) provide an antioxidant activity in preventing dopaminergic neurons from degeneration. However, the underlying and related molecular details remain poorly understood. METHODS AND AIM: We review published in vitro and rodent studies of natural products in PD models with the aim to identify common molecular pathways contributing to the treatment efficacy. Commonly regulated genes were identified through the systemic literature search and further analyzed from a network perspective. FINDINGS: Approximately thirty different types of natural products have been investigated for their ability to regulate protein density and gene activity in various experimental systems. Most were found to attenuate neurotoxin-induced regulations. Three common PD pathways are involved. The most studied pathway was neuronal development/anti-apoptosis consisting of Bax/Bcl-2, caspases 3/9, and MAPK signaling. Another well studied was anti-inflammation comprising iNOS, nNOS, Nrf2/ARE, cytokines, TNFα, COX2 and MAPK signaling. The third pathway referred to dopamine transmission modulation with upregulated VMAT2, DAT, NURR1 and GDNF levels. To date, HIPK2, a conserved serine/threonine kinase and transcriptional target of Nrf2 in an anti-apoptosis signaling pathway, is the first protein identified as the direct binding target of a natural product (ZMHC). IMPLICATIONS: Natural products may utilize multiple and intercellular pathways at various steps to prevent DA neurons from degeneration. Molecular delineation of the mechanisms of actions is revealing new, perhaps combinational therapeutic approaches to stop the progression of DA degeneration.
650    _2
$a zvířata $7 D000818
650    _2
$a antiflogistika $x chemie $x farmakologie $7 D000893
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a biologické přípravky $x chemie $x farmakologie $7 D001688
650    _2
$a dopamin $x metabolismus $7 D004298
650    _2
$a dopaminergní neurony $x účinky léků $x metabolismus $7 D059290
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x farmakoterapie $7 D007249
650    _2
$a myši $7 D051379
650    _2
$a Parkinsonova nemoc $x farmakoterapie $7 D010300
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a nervový přenos $x účinky léků $7 D009435
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Long, Xi $u Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
700    1_
$a Hu, Jichuan $u Department of Neurology, People's Hospital of Dongxihu District, Wuhan, Hubei 430040, China.
700    1_
$a Bi, Juan $u Department of Neurology, People's Hospital of Dongxihu District, Wuhan, Hubei 430040, China.
700    1_
$a Zhou, Ting $u Department of Neurology, People's Hospital of Dongxihu District, Wuhan, Hubei 430040, China.
700    1_
$a Guo, Xingfang $u Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
700    1_
$a Han, Chao $u Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; Department of Neurology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
700    1_
$a Huang, Jinsha $u Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
700    1_
$a Wang, Tao $u Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
700    1_
$a Xiong, Nian $u Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; Department of Neurology, People's Hospital of Dongxihu District, Wuhan, Hubei 430040, China. Electronic address: nianxiong@hust.edu.cn.
700    1_
$a Lin, Zhicheng $u Laboratory of Psychiatric Neurogenomics, McLean Hospital, Harvard Medical School, Belmont, MA 02478, United States. Electronic address: zlin@mclean.harvard.edu.
773    0_
$w MED00003830 $t Phytomedicine : international journal of phytotherapy and phytopharmacology $x 1618-095X $g Roč. 60, č. - (2019), s. 152954
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31130327 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200116105726 $b ABA008
999    __
$a ok $b bmc $g 1483068 $s 1083472
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 60 $c - $d 152954 $e 20190511 $i 1618-095X $m Phytomedicine $n Phytomedicine $x MED00003830
GRA    __
$a R01 DA021409 $p NIDA NIH HHS $2 United States
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options